Johns Hopkins Present Positive Study Results For Sienna’s hTERT Test

17-Mar-2018
    • 500 patient study confirms clinical utility of hTERT testing as an adjunct to urine cytology
    • Study results were presented by Johns Hopkins at USCAP meeting in Vancouver

Sienna is pleased to announce that renowned research institute, Johns Hopkins University School of Medicine, has today presented the results of its study using Sienna’s in-vitro diagnostic (IVD) hTERT test at the United States and Canadian Academy of Pathology (USCAP) 2018 Annual Meeting.

The 500-patient bladder cancer study confirmed the clinical utility of the test as an adjunct to urine cytology. The results demonstrated an increase in sensitivity when using the hTERT test in conjunction with cytology. The sensitivity of standard urine cytology alone was 29.2%, whereas cytology combined with hTERT increased the sensitivity to 50.8%, while maintaining a specificity of 89.2%. As a result, the study concluded that hTERT testing may help to identify patients with increased likelihood of High Grade Urothelial Carcinoma (HGUC), who may otherwise be missed by standard screening alone. Additionally, negative hTERT staining was shown to be associated with a decreased risk of HGUC compared to cytology alone.

The USCAP Annual Meeting is a premier event for pathologists drawing over 5,000 attendees from almost 90 countries. This year’s conference is being held in Vancouver, Canada from March 17-23, 2018.

Sienna’s CEO Matthew Hoskin commented: “We are delighted with the results of the study, demonstrating that our hTERT test provides valuable additional information to physicians. Having the results presented at such a prestigious gathering of pathologists will provide the hTERT test great exposure to laboratories who may ultimately offer it as part of their testing menu.”

The results of the study were presented by Professor Christopher VandenBussche, associate director of cytopathology and assistant professor of pathology, and Dr Morgan Cowan, resident pathologist, both of the Johns Hopkins University School of Medicine.

In a video release, Sienna’s CEO Matthew Hoskin discusses the positive findings of the clinical study investigating the use of the hTERT test as an adjunct to urine cytology for the investigation of bladder cancer. He also delves into the significance of the trial’s findings for the Company, the significant market opportunity and commercialisation progress made to date.

view the study ("poster") presentation


To view the study ("poster") presentation, click here: http://bit.ly/2IFpq1B

Video Interview



 
Comment

No Very




Captcha Image

Sign up for updates